These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 26967126)

  • 1. Safety and tolerability of antipsychotic co-treatment in patients with schizophrenia: results from a systematic review and meta-analysis of randomized controlled trials.
    Galling B; Roldán A; Rietschel L; Hagi K; Walyzada F; Zheng W; Cao XL; Xiang YT; Kane JM; Correll CU
    Expert Opin Drug Saf; 2016 May; 15(5):591-612. PubMed ID: 26967126
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of adjunctive topiramate for schizophrenia: a meta-analysis of randomized controlled trials.
    Zheng W; Xiang YT; Xiang YQ; Li XB; Ungvari GS; Chiu HF; Correll CU
    Acta Psychiatr Scand; 2016 Nov; 134(5):385-398. PubMed ID: 27585549
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy for Psychopathology and Body Weight and Safety of Topiramate-Antipsychotic Cotreatment in Patients With Schizophrenia Spectrum Disorders: Results From a Meta-Analysis of Randomized Controlled Trials.
    Correll CU; Maayan L; Kane J; Hert MD; Cohen D
    J Clin Psychiatry; 2016 Jun; 77(6):e746-56. PubMed ID: 27337425
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of antidepressant augmentation of continued antipsychotic treatment in patients with schizophrenia.
    Galling B; Vernon JA; Pagsberg AK; Wadhwa A; Grudnikoff E; Seidman AJ; Tsoy-Podosenin M; Poyurovsky M; Kane JM; Correll CU
    Acta Psychiatr Scand; 2018 Mar; 137(3):187-205. PubMed ID: 29431197
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High dose antipsychotic polypharmacy and dopamine partial agonists - time to rethink guidelines?
    Reynolds GP
    J Psychopharmacol; 2021 Sep; 35(9):1030-1036. PubMed ID: 34256637
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antagonist and partial agonist at the dopamine D2 receptors in drug-naïve and non-drug-naïve schizophrenia: a randomized, controlled trial.
    Takekita Y; Fabbri C; Kato M; Nonen S; Sakai S; Sunada N; Koshikawa Y; Wakeno M; Okugawa G; Kinoshita T; Serretti A
    Eur Arch Psychiatry Clin Neurosci; 2015 Oct; 265(7):579-88. PubMed ID: 26016467
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and tolerability of perospirone in schizophrenia: a systematic review and meta-analysis of randomized controlled trials.
    Kishi T; Iwata N
    CNS Drugs; 2013 Sep; 27(9):731-41. PubMed ID: 23812802
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association With Hospitalization and All-Cause Discontinuation Among Patients With Schizophrenia on Clozapine vs Other Oral Second-Generation Antipsychotics: A Systematic Review and Meta-analysis of Cohort Studies.
    Masuda T; Misawa F; Takase M; Kane JM; Correll CU
    JAMA Psychiatry; 2019 Oct; 76(10):1052-1062. PubMed ID: 31365048
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antipsychotic augmentation vs. monotherapy in schizophrenia: systematic review, meta-analysis and meta-regression analysis.
    Galling B; Roldán A; Hagi K; Rietschel L; Walyzada F; Zheng W; Cao XL; Xiang YT; Zink M; Kane JM; Nielsen J; Leucht S; Correll CU
    World Psychiatry; 2017 Feb; 16(1):77-89. PubMed ID: 28127934
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and tolerability of antidepressant co-treatment in acute major depressive disorder: results from a systematic review and exploratory meta-analysis.
    Galling B; Calsina Ferrer A; Abi Zeid Daou M; Sangroula D; Hagi K; Correll CU
    Expert Opin Drug Saf; 2015 Oct; 14(10):1587-608. PubMed ID: 26360500
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ECT augmentation of clozapine for clozapine-resistant schizophrenia: A meta-analysis of randomized controlled trials.
    Wang G; Zheng W; Li XB; Wang SB; Cai DB; Yang XH; Ungvari GS; Xiang YT; Correll CU
    J Psychiatr Res; 2018 Oct; 105():23-32. PubMed ID: 30144667
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antipsychotic combinations vs monotherapy in schizophrenia: a meta-analysis of randomized controlled trials.
    Correll CU; Rummel-Kluge C; Corves C; Kane JM; Leucht S
    Schizophr Bull; 2009 Mar; 35(2):443-57. PubMed ID: 18417466
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Brexpiprazole for schizophrenia and as adjunct for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antipsychotic - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?
    Citrome L
    Int J Clin Pract; 2015 Sep; 69(9):978-97. PubMed ID: 26250067
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An open, large, 6-month naturalistic study of outcome in schizophrenic outpatients, treated with olanzapine.
    Krzystanek M; Krupka-Matuszczyk I
    Hum Psychopharmacol; 2011 Jan; 26(1):81-5. PubMed ID: 23055416
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of noradrenalin reuptake inhibitor augmentation therapy for schizophrenia: a meta-analysis of double-blind randomized placebo-controlled trials.
    Kishi T; Mukai T; Matsuda Y; Moriwaki M; Iwata N
    J Psychiatr Res; 2013 Nov; 47(11):1557-63. PubMed ID: 23899496
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selective serotonin 3 receptor antagonist treatment for schizophrenia: meta-analysis and systematic review.
    Kishi T; Mukai T; Matsuda Y; Iwata N
    Neuromolecular Med; 2014 Mar; 16(1):61-9. PubMed ID: 23896722
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Benzodiazepine augmentation of antipsychotic drugs in schizophrenia: a meta-analysis and Cochrane review of randomized controlled trials.
    Dold M; Li C; Gillies D; Leucht S
    Eur Neuropsychopharmacol; 2013 Sep; 23(9):1023-33. PubMed ID: 23602690
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Amantadine for Antipsychotic-Related Weight Gain: Meta-Analysis of Randomized Placebo-Controlled Trials.
    Zheng W; Wang S; Ungvari GS; Ng CH; Yang XH; Gu YH; Li M; Xiang YQ; Xiang YT
    J Clin Psychopharmacol; 2017 Jun; 37(3):341-346. PubMed ID: 28383359
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and tolerability of minocycline augmentation therapy in schizophrenia: a systematic review and meta-analysis of randomized controlled trials.
    Oya K; Kishi T; Iwata N
    Hum Psychopharmacol; 2014 Sep; 29(5):483-91. PubMed ID: 25087702
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NMDA receptor antagonists interventions in schizophrenia: Meta-analysis of randomized, placebo-controlled trials.
    Kishi T; Iwata N
    J Psychiatr Res; 2013 Sep; 47(9):1143-9. PubMed ID: 23692933
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.